XML 51 R28.htm IDEA: XBRL DOCUMENT
v3.20.1

FAIR VALUE MEASUREMENTS (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Fair Value Disclosures [Abstract] |
Fair Value, Measurement Inputs | A summary of the significant inputs is as follows:
Business Acquisition |  | Benchmark |  | Comparable Company Revenue Volatility |  | Discount rate |  | Maximum Contingent Consideration Payment
Certain assets of the clinical and anatomic pathology laboratory business of Shiel Holdings, LLC |  | Volume |  | 6.9% |  | 4.5% |  | $ | 15 |
ReproSource, Inc. |  | Revenue |  | 8.5% |  | 6.5% |  | $ | 10 |
The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
|  |  | Basis of Fair Value Measurements
|  |  | Quoted Prices in Active Markets for Identical Assets/Liabilities |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs
March 31, 2020 | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |  |  |  |
Trading securities | $ | 52 |  |  | $ | 52 |  |  | $ | — |  |  | $ | — |
Cash surrender value of life insurance policies | 36 |  |  | — |  |  | 36 |  |  | — |
Available-for-sale debt securities | 12 |  |  | — |  |  | — |  |  | 12 |
Fixed-to-variable interest rate swaps | 41 |  |  | — |  |  | 41 |  |  | — |
Total | $ | 141 |  |  | $ | 52 |  |  | $ | 77 |  |  | $ | 12 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |
Deferred compensation liabilities | $ | 95 |  |  | $ | — |  |  | $ | 95 |  |  | $ | — |
Contingent consideration | 6 |  |  | — |  |  | — |  |  | 6 |
Total | $ | 101 |  |  | $ | — |  |  | $ | 95 |  |  | $ | 6 |
Redeemable noncontrolling interest | $ | 76 |  |  | $ | — |  |  | $ | — |  |  | $ | 76 |
|  |  | Basis of Fair Value Measurements
December 31, 2019 | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |  |  |  |
Trading securities | $ | 59 |  |  | $ | 59 |  |  | $ | — |  |  | $ | — |
Cash surrender value of life insurance policies | 43 |  |  | — |  |  | 43 |  |  | — |
Available-for-sale debt securities | 12 |  |  | — |  |  | — |  |  | 12 |
Total | $ | 114 |  |  | $ | 59 |  |  | $ | 43 |  |  | $ | 12 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |
Deferred compensation liabilities | $ | 110 |  |  | $ | — |  |  | $ | 110 |  |  | $ | — |
Fixed-to-variable interest rate swaps | 28 |  |  | — |  |  | 28 |  |  | — |
Contingent consideration | 7 |  |  | — |  |  | — |  |  | 7 |
Total | $ | 145 |  |  | $ | — |  |  | $ | 138 |  |  | $ | 7 |
Redeemable noncontrolling interest | $ | 76 |  |  | $ | — |  |  | $ | — |  |  | $ | 76 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation | The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3 of the fair value hierarchy):
| Contingent Consideration
Balance, December 31, 2019 | $ | 7 |
Total gains/losses included in earnings - realized/unrealized | (1 | )
Balance, March 31, 2020 | $ | 6 |

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -URI http://asc.fasb.org/topic&trid=2155941 + Details
Name: | us-gaap_FairValueMeasurementInputsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration